AMR Action Fund logo

AMR Action Fund

North America, Massachusetts, United States, Boston

Description

AMR Action Fund renders investment, healthcare, biotech, research and development, pharmaceutical, and antibiotic services.

Investor Profile

AMR Action Fund has made 8 investments, with 3 in the past 12 months and 88% as lead.

Stage Focus

  • Series B (38%)
  • Series E (25%)
  • Post Ipo Equity (13%)
  • Series C (13%)
  • Series H (13%)

Country Focus

  • United States (63%)
  • Israel (13%)
  • France (13%)
  • United Kingdom (13%)

Industry Focus

  • Biotechnology
  • Medical
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Business Development
  • Life Science
  • Medical Device
  • Genetics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does AMR Action Fund frequently co-invest with?

Bill & Melinda Gates Foundation
North America, New York, United States, New York
Co-Investments: 1
Deerfield Management
North America, New York, United States, New York
Co-Investments: 2
AN
North America, California, United States, Santa Monica
Co-Investments: 1
AXA Investment Managers
Europe, Ile-de-France, France, Puteaux
Co-Investments: 1
KOREA INVESTMENT & SECURITIES
Asia, Seoul-t'ukpyolsi, South Korea, Yongdungpo
Co-Investments: 1
Korea Investment Partners
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 1
Korea Investment Holdings
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 1
K2 HealthVentures
North America, Massachusetts, United States, Boston
Co-Investments: 1
Peak 6
North America, Illinois, United States, Chicago
Co-Investments: 1
Co-Investments: 1

Which angels does AMR Action Fund often collaborate with?

CR
Europe, Geneve, Switzerland, Geneva
Shared Deals: 1

What are some of recent deals done by AMR Action Fund?

TenNor Therapeutics

Westfield, New Jersey, United States

TenNor Therapeutics specializes in research and development of new drugs for the treatment of digestive diseases

BiotechnologyMedicalTherapeutics
Series EOct 16, 2024
Amount Raised: $42,138,382
F2G

Manchester, Manchester, United Kingdom

F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.

BiotechnologyGeneticsHealth CareMedicalPharmaceutical
Series HSep 12, 2024
Amount Raised: $100,000,000
Elion Therapeutics

Boston, Massachusetts, United States

Elion Therapeutics is a cutting-edge biotechnology business focused on treating life-threatening IFIs

BiotechnologyPharmaceuticalTherapeutics
Series BJun 17, 2024
Amount Raised: $81,000,000
BIOMx

Ness Ziona, HaMerkaz, Israel

BIOMx is a microbiome therapeutics company developing synbio phage therapies to eradicate harmful bacteria in chronic diseases.

BiotechnologyHealth CareTherapeutics
Post Ipo EquityMar 6, 2024
Amount Raised: $50,000,000
Antabio

Labège, Midi-Pyrenees, France

Antabio is a private biopharmaceutical company developing antibacterial resistance-breakers in areas of highest medical need.

BiotechnologyLife ScienceMedical Device
Series BDec 12, 2023
Amount Raised: $26,996,237
Adaptive Phage Therapeutics

Bethesda, Maryland, United States

Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria.

BiotechnologyHealth CarePharmaceuticalTherapeutics
Series BJun 13, 2023
Amount Raised: $12,000,000
Vedanta Biosciences

Cambridge, Massachusetts, United States

Vedanta Biosciences creates microbiome-derived therapies to address immune and infectious diseases by modulating the gut microbiota.

BiotechnologyBusiness DevelopmentMedical
Series EApr 25, 2023
Amount Raised: $106,500,000
Venatorx Pharmaceuticals

Malvern, Pennsylvania, United States

Venatorx Pharmaceuticals develops anti-infectives to treat multi-drug-resistant bacterial infections and viral infections.

Health CareMedicalPharmaceutical
Series CApr 4, 2022
Amount Raised: $34,000,000